London – December 16, 2021 – Cooley advised Biote, a medical practice-building business within the hormone optimization space, on its definitive business combination agreement with special purpose acquisition company (SPAC) Haymaker Acquisition Corp III. Lawyers Michal Berkner and Jarrett Burks led the Cooley team advising Biote.
The implied initial equity value of the business combination is approximately $737 million, with the combined company expected to have $195 million in cash after closing, assuming no Haymaker stockholders elect to have their shares redeemed. The business combination is expected to be completed in 1H of 2022 and, the combined company will be listed on the Nasdaq Stock Market under the symbol BTMD.
“Biote has a huge opportunity to enable physicians to help this highly underserved patient population take greater control of their health,” Terry Weber, CEO of Biote, said in a news release. “Biote is committed to educating and empowering providers to effectively treat patients and help them understand the critical role that hormones play in healthy aging. We welcome Haymaker as partners and look forward to the role our status as a public company will play in increasing access to, and awareness of, our leading hormone therapy practice-building business.”
Biote provides the necessary components to enable practitioners to establish, build and successfully operate a hormone optimization center to treat patients appropriate for therapy. The company trains practitioners on how to identify and treat early indicators of hormone-related aging conditions.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,500 lawyers across 17 offices in the United States, Asia and Europe.